Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

Pivotal Trial in Medullary Thyroid Cancer Planned to Initiate This Summer

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of XL184, a small molecule anticancer compound targeting MET, RET, and VEGFR2, via the Special Protocol Assessment process. Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the phase 3 trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) this summer.

The phase 3 trial has been designed in collaboration with internationally renowned experts in the field of thyroid malignancies, including Dr. Steven Sherman from the MD Anderson Cancer Center in Houston, Texas, Drs. Douglas Ball and Barry Nelkin from Johns Hopkins University in Baltimore, Maryland, and Dr. Martin Schlumberger from the Institut Gustave Roussy in Paris, France. This will be a randomized, placebo-controlled, double-blinded study of XL184 as single-agent therapy in 315 patients with unresectable, locally advanced, or metastatic MTC. Patients will be randomized in a 2:1 ratio to receive XL184 or placebo administered as a daily oral dose. The primary endpoint will be duration of progression-free survival. In a planned event-driven analysis, the study size provides 90% power to detect a 75% increase in progression-free survival in patients with documented progressive disease prior to study entry. Secondary endpoints will include overall survival, objective tumor response rate, and changes in serum biomarkers (carcinoembryonic antigen and calcitonin). Additional secondary endpoints will b
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Genera ... feedstock supply innovation and supply chain advancements, has ... management systems, Energy Grange™ and Supply ASSURE™. ... and in-the-field testing aimed at consolidating and simplifying ... to landowners, farmers and feedstock end users. , ...
(Date:7/29/2014)... G-CON Manufacturing Inc., the standard in ... a new leadership appointment designed to drive the company’s ... , Maik Jornitz, Chief Operating Officer of G-Con ... with leading the pioneering company through its next phase ... of development and look forward to providing our next ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 White ... devices, and cloud based eClinical technologies, have been published ... Online. These follow a long line of white papers ... publications including Life Science Leader, Pharmaceutical Online, and OpenHealthNews. ... provided a paper by CTO Marc Desgrousilliers, 'The ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, announced ... has developed an issue brief titled, “What is the ... Workgroup, a part of WEDI’s Strategic National HPID Implementation ... Medicaid Services (CMS) to identify common misuse of the ...
Breaking Biology Technology:Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2
... wholly-owned subsidiary Embryome Sciences, Inc., have signed ... Stem Cell Corporation (OTCBB:ISCO) through its wholly-owned ... produce and distribute hundreds of new standardized ... with corresponding data and reagents. The mutual ...
... BOSTON, June 24 PAREXEL International,Corporation (Nasdaq: PRXL ... for the fourth quarter of Fiscal Year,2008 (ending June ... and for,Fiscal Year 2009 at its Investor Day being ... none of these estimates include the,impact from the potential ...
... highest environmental award,from EPA, COLUMBUS, Ohio, June ... development organization, today,announced its work in developing bio-based ... Chemistry Award from the EPA., The award ... Chemistry,Challenge Awards ceremony in Washington, D.C. on June ...
Cached Biology Technology: BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 3 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 4 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 5PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day 2PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day 3PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day 4Battelle Earns 2008 Presidential Green Chemistry Award 2
(Date:7/29/2014)... UC San Francisco is the first to show that ... accelerate cellular aging, these negative effects may be reduced ... , "The study participants who exercised, slept well ... ones who didn,t maintain healthy lifestyles, even when they ... Puterman, PhD, assistant professor in the department of psychiatry ...
(Date:7/28/2014)... of two additional coral communities showing signs of damage from ... the 2010 spill in the Gulf of Mexico. The discovery ... of biology at Penn State University. A paper describing this ... the Gulf of Mexico will be published during the last ... the journal Proceedings of the National Academy of Sciences ...
(Date:7/28/2014)... international team of researchers led by the University of ... , The genetic information will enhance scientists, and agriculturalists, ... well as enable the development of new rice varieties ... stressors to help solve global hunger challenges. , The ... glaberrima ) and evidence for independent domestication," was published ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4
... protein made by a cancer virus causes infected immune cells ... spread. , The virus, the human T lymphotropic virus ... as T lymphocytes, or T cells, touch uninfected T cells. ... happens. It suggests that an HTLV-1 protein known as p12 ...
... kidney disease, report scientists at the University of California, Santa ... the Proceedings of the National Academies of Science published the ... called sirolimus, and is currently used as an immunosuppressant, to ... , Over 600,000 people in the U.S., and 12 million ...
... Concerns about the use of letrozole, an easy-to-use ... appear to be unfounded, according to a major ... Division of Reproductive Endocrinology and Infertility, McGill University ... Gynecology at the Jewish General Hospital, and Professor ...
Cached Biology News:Viral protein helps infected T cells stick to uninfected cells 2Scientists discover that widely available drug also helps fight kidney disease 2Scientists discover that widely available drug also helps fight kidney disease 3Fertility drugs given 'all-clear' in new study 2
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
Rab1A...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: